Congress expands drug-detection mandate to emerging synthetic opioid threat
H.R. 8022 — DETECT Nitazenes Act of 2026 · Filed by August Pfluger (R-TX) · 2 cosponsors · Introduced Mar 19, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the Department of Homeland Security's Science and Technology Directorate to work with the Drug Enforcement Agency to develop detection and identification technology for nitazenes—a synthetic opioid—at very low concentrations, similar to existing efforts for fentanyl and xylazine. It amends the Homeland Security Act to add nitazenes to the list of drugs the DHS is tasked with detecting and disrupting.
Why we flagged it
The bill is a straightforward expansion of existing federal drug-detection authority to include a newly emergent synthetic opioid. It is a technical amendment to existing law with a clear public-health purpose—no private benefit, no deregulation, no carve-out.
What the text implies
- Nitazenes are increasingly appearing in illicit drug supplies mixed with fentanyl and other opioids; adding them to the DHS detection mandate may improve overdose-prevention efforts by enabling earlier identification of contaminated supplies.
- The bill does not appropriate funds or specify implementation timelines, so effectiveness depends on future budget allocation and DEA/DHS coordination—outcomes are not guaranteed by the statute alone.
- Expanding detection capacity for synthetic opioids may create secondary benefits for border security and port-of-entry screening, though the bill does not explicitly mandate those applications.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
The bill expands public-health and law-enforcement capacity to detect and disrupt an emerging synthetic opioid threat (nitazenes) without imposing new restrictions on citizens or creating private carve-outs. Citizens benefit from enhanced detection infrastructure aimed at preventing illicit drug distribution.
Named in the bill
Department of Homeland Security, Science and Technology Directorate, Drug Enforcement Agency, Homeland Security Act of 2002
Where it stands
2 cosponsors: 1 Democrats, 1 Republicans.
- Mar 19, 2026 — Introduced · Congress.gov: “Introduced in House”
- Mar 19, 2026 — Referred to House Committee on Homeland Security · Congress.gov: “Referred to the House Committee on Homeland Security”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $240,000 in lobbying spend. A filing names 99 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 0% of bills with at least one filing.
August Pfluger, the sponsor, reported $1,070,325 in PAC receipts in the 2026 cycle.
- Fdd Action — $240,000 on 1 filing
Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (435 characters) on Aug 21, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Jun 2026 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 20, 2026 · page rendered 2026-10-20.
“Congress expands drug-detection mandate to emerging synthetic opioid threat” QuorumCivic. https://share.quorumcivic.app/bill/119/hr8022 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.